Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

ClinicalTrials.gov ID: NCT00003401

Public ClinicalTrials.gov record NCT00003401. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Autologous Transplantation With Gemcitabine and High Dose BCNU Plus Melphalan Followed by Consolidation With DCEP Plus Gemcitabine and Taxol/Cisplatin in Patients With Multiple Myeloma and >12 Months of Standard Therapy

Study identification

NCT ID
NCT00003401
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
University of Maryland, Baltimore
Other
Enrollment
Not listed

Conditions and interventions

Interventions

  • bone marrow ablation with stem cell support Procedure
  • carmustine Drug
  • cisplatin Drug
  • cyclophosphamide Drug
  • dexamethasone Drug
  • etoposide Drug
  • gemcitabine hydrochloride Drug
  • melphalan Drug
  • paclitaxel Drug
  • peripheral blood stem cell transplantation Procedure

Procedure · Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 1998
Primary completion
Aug 31, 2002
Completion
Aug 31, 2002
Last update posted
Oct 16, 2019

1999 – 2002

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Marlene & Stewart Greenebaum Cancer Center, University of Maryland Baltimore Maryland 21201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00003401, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 16, 2019 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00003401 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →